scholarly journals Proximal Glycans Outside of the Epitopes Regulate the Presentation of HIV-1 Envelope gp120 Helper Epitopes

2009 ◽  
Vol 182 (10) ◽  
pp. 6369-6378 ◽  
Author(s):  
Hualin Li ◽  
Chong-Feng Xu ◽  
Steven Blais ◽  
Qi Wan ◽  
Hui-Tang Zhang ◽  
...  
Keyword(s):  
Hiv 1 ◽  
2013 ◽  
Vol 13 (16) ◽  
pp. 1907-1915 ◽  
Author(s):  
Bart Hoorelbeke ◽  
Youngju Kim ◽  
Toshikazu Oki ◽  
Yasuhiro Igarashi ◽  
Jan Balzarini
Keyword(s):  
Hiv 1 ◽  

Author(s):  
Agustin Valenzuela ◽  
Julià Blanco ◽  
Christian Callebaut ◽  
Etienne Jacotot ◽  
Carmen Lluis ◽  
...  

Virology ◽  
2004 ◽  
Vol 321 (1) ◽  
pp. 75-86 ◽  
Author(s):  
Ira Berkower ◽  
Megan Raymond ◽  
Jacqueline Muller ◽  
Angelo Spadaccini ◽  
Anne Aberdeen

Vaccine ◽  
2009 ◽  
Vol 28 (2) ◽  
pp. 352-360 ◽  
Author(s):  
Catarina E. Hioe ◽  
Maria Luisa Visciano ◽  
Rajnish Kumar ◽  
Jianping Liu ◽  
Ethan A. Mack ◽  
...  

2008 ◽  
Vol 180 (6) ◽  
pp. 4011-4021 ◽  
Author(s):  
Hualin Li ◽  
Peter C. Chien ◽  
Michael Tuen ◽  
Maria Luisa Visciano ◽  
Sandra Cohen ◽  
...  

Author(s):  
I. A. Kashyn ◽  
G. I. Nikolaev ◽  
M. A. Tuzikov ◽  
A. M. Andrianov

Molecular dynamics simulations for the structural complexes of potential HIV-1 inhibitors with the viral envelope gp120 protein were carried out. Free energies of the formation of these supramolecular structures and contributions of individual amino-acid residues of gp120 to the enthalpy binding were calculated. The residues of gp120 critical for interactions with the ligands were identified. Based on the data obtained, five compounds promising for synthesis and testing for antiviral activity were selected. It is suggested that these compounds may be successfully used in the design of novel, potent and broad anti-HIV drugs.


Pathogens ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 425
Author(s):  
Chih-Yen Lin ◽  
Wen-Hung Wang ◽  
Szu-Wei Huang ◽  
Chun-Sheng Yeh ◽  
Ruei-Yu Yuan ◽  
...  

HIV-1 CRF07_BC is a B’ and C subtype recombinant emerging virus and many of its viral characteristics remain unclear. Galectin-3 (Gal3) is a β-galactose binding lectin that has been reported as a pattern recognition receptor (PRR) and is known to mediate adhesion between cells and microbes. This study aims to examine the viral characteristics of HIV-1 CRF07_BC virus and the role of extracellular galectin-3 in HIV-1 CRF07_BC infection. A total of 28 HIV-1+ injecting drug users (IDUs) were recruited and 24 (85.7%) were identified as HIV-1 CRF07_BC. Results indicate that significant higher serum galectin-3 was measured in CRF07_BC infected patients and CRF07_BC infection triggered significant galectin-3 expression (p < 0.01). Viral characteristics demonstrate that CRF07_BC virions display a higher level of envelope gp120 spikes. The virus infectivity assay demonstrated that co-treatment with galectin-3 significantly promoted CRF07_BC attachment and internalization (p < 0.01). A co-immunoprecipitation assay showed that pulldown galectin-3 co-precipitated both CD4 and gp120 proteins. Results from an enzyme-linked immunosorbent assay (ELISA) indicate that the galectin-3 promoting effect occurs through enhancement of the interaction between gp120 and CD4. This study suggests that CRF07_BC was predominant in HIV-1+ IDUs and CRF07_BC utilized extracellular galectin-3 to enhance its infectivity via stabilization of the gp120-CD4 interaction.


Sign in / Sign up

Export Citation Format

Share Document